Human papillomavirus, vaccines and women's health: Questions and cautions

CMAJ. Canadian Medical Association Journal

Volumn 177, Issue 5, 2007, Pages 484-487

  Lippman, Abby ^a,b   Melnychuk, Ryan ^c   Shimmin, Carolyn ^b   Boscoe, Madeline ^d  

^a MCGILL UNIVERSITY   (Canada)

^b Canadian Women's Health Network   (Canada)

^c DALHOUSIE UNIVERSITY   (Canada)

^d Women's Health Clinic   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

WART VIRUS VACCINE;

CANADA; CANCER INCIDENCE; CANCER MORTALITY; DECISION MAKING; EVIDENCE BASED PRACTICE; HUMAN; IMMUNIZATION; NOTE; PUBLIC HEALTH; UTERINE CERVIX CANCER; VACCINATION; VIRUS INFECTION; WART VIRUS; WOMEN'S HEALTH;

EID: 34548402886     PISSN: 08203946     EISSN: 14882329     Source Type: Journal    
DOI: 10.1503/cmaj.070944     Document Type: Note

References (11)

1. National Advisory Committee on Immunization. Statement on human papillomavirus vaccine. Can Commun Dis Rep 2007;33(ACS-2):1-31. Available: www.phac-aspc.gc.ca/publicat/ccdr-rmtc/07pdf/acs33-02.pdf (accessed 2007 July 17).
2. Erickson LJ, De Wals P, Farand L. An analytical framework for immunization programs in Canada. Vaccine 2005;23:2470-6.
3. Public Health Agency of Canada. Canadian human papillomavirus vaccine research priorities workshop: final report. Can Commun Dis Rep 2006;32S1:1-66. Available: www.phac-aspc.gc.ca/publicat/ccdr-rmtc/06vol32/32s1/ index.html (accessed 2007 July 17).
4. Canadian Cancer Society and National Cancer Institute of Canada. Canadian cancer statistics 2006. Toronto: The Institute; 2006.
5. Sellors JW, Lytwyn A. Human papilloma virus. [In: National goals for the prevention and control of sexually transmitted diseases in Canada.] Can Commun Dis Rep 1997 Nov; 23S6. Available: www.phac-aspc.gc.ca/publicat/ccdr- rmtc/97vol23/23s6nat/23s6g_e.html (accessed 2007 July 17).
6. James PD, Wilkins R, Detsky AS, et al. Avoidable mortality by neighbourhood income in Canada: 25 years after the establishment of universal health insurance. J Epidemiol Community Health 2007;61:287-96.
7. Management and treatment of specific infections: genital human papillomavirus (HPV) infections. In: Canadian guidelines on sexually transmitted infections, 2006 edition. Ottawa: Public Health Agency of Canada; 2006. Available: www.phac-aspc.gc.ca/std-mts/sti_2006/sti_intro2006_e. html (accessed 2007 July 23).
8. Public Health Agency of Canada. What everyone should know about human papillomavirus (HPV): questions and answers. Available: www.phac-aspc.gc.ca/std- mts/hpv-vph/hpv-vph-qaqr_e.html (accessed 2007 July 17).
9. Rambout L, Hopkins L, Hutton B, et al. Prophylactic vaccination against human papillomavirus infection and disease in women: a systematic review of randomized controlled trials. CMAJ 2007;177:469-79.
10. Chaves SS, Gargiullo P, Zhang JX, et al. Loss of vaccine-induced immunity to varicella over time. N Engl J Med 2007;356:1121-9.
11. Rabin R. A new vaccine for girls: But should it be compulsory? New York Times 2006 Jul 18. Available: http://query.nytimes.com/gst/fullpage. html?sec=health&res=9E06E7DF163FF93BA25754CoA9609C8B63 (accessed 2007 July 23).